|
|
Article: Corautus Stock Plunges After Enrollment Halted In Phase II.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Shares in Corautus Genetics Inc. tumbled by nearly two-thirds Monday following the Atlanta company's announcement that it would stop a Phase IIb trial in angina patients who are not suitable for traditional revascularization procedures.
The stock (NASDAQ:VEGF) plummeted 68.5 percent, or $2.33, to close at $1.07 on heavy trading. Corautus decided to terminate patient enrollment in the GENASIS (Genetic Angiogenic Stimulation Investigational Study) trial of its VEGF-2 product based on the recommendation of an independent data monitoring committee, which saw very little chance for significant efficacy on the trial's primary endpoint ...